RNS Number : 7467N Reckitt Benckiser Group PLC 27 November 2024

## RECKITT BENCKISER GROUP PLC DIRECTORATE CHANGE

## Reckitt announces the appointment of Mahesh Madhavan and Stefan Oschmann as Non-Executive Directors

Reckitt Benckiser Group plc (the "**Company**" or "**Reckitt**") today announces the appointment of Mahesh Madhavan, current CEO of Bacardi and Stefan Oschmann, former CEO of Merck KGaA, to the Board as Non-Executive Directors, effective 1 January 2025.

Mahesh is CEO of Bacardi Ltd having joined in 1997 and held a number of regional leadership roles before being promoted to CEO in 2017. Since becoming CEO he has led a successful transformation of the business, providing stability and a clear strategy for success to the organisation. Previously, Mahesh held various roles at International Distillers & Vintners, FCB Ulka Advertising and Wipro Consumer products.

Mahesh is currently a Non-Executive Director of Capri Holdings.

Mahesh will join the Remuneration Committee from February 2025.

Stefan Oschmann is the former CEO and Chair of Merck KGaA which he joined in 2011 as a member of the Executive Board and CEO of Merck Biopharma and held a number of senior leadership roles within the healthcare business before becoming CEO and Chair of Merck between 2016 and 2021. Prior to that Stefan spent 30 years at Merck & Co in various leadership roles. Stefan brings strong transformational experience in science, healthcare and technology.

Stefan is currently a Non-Executive Director at Stamm, European Healthcare Acquisition & Growth, Springer Nature and is Chair of AiCuris Anti-Infective Cures.

Stefan will join the Compliance Committee from February 2025.

Commenting on the appointment, Sir Jeremy Darroch, Chair of the Board said:

"I am delighted that Mahesh and Stefan have agreed to join the Reckitt Board. They are both outstanding leaders, with many years' experience as CEO's of large global businesses. We welcome the value and expertise both will bring to the Board."

The Company confirms that there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to the appointments.

Contact Details:

Catheryn O'Rourke General Counsel & Company Secretary +44 (0) 1753 217 800

Nick Ashworth Investor Relations +44 (0) 7408 812350

About Reckitt:

Reckitt\* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege.

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.

Every day, more than 20 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always.

We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at <u>www.reckitt.com</u>

\* Reckitt is the trading name of the Reckitt Benckiser group of companies

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

BOAPPGQAGUPCGQQ